These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36163489)

  • 1. Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy.
    Jalil A; Ivanova T; Moussa G; Parry NRA; Black GCM
    Eye (Lond); 2023 Jun; 37(9):1874-1877. PubMed ID: 36163489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
    Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
    Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
    Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
    Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
    Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
    Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
    Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
    Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec.
    Stingl K; Kempf M; Bartz-Schmidt KU; Dimopoulos S; Reichel F; Jung R; Kelbsch C; Kohl S; Kortüm FC; Nasser F; Peters T; Wilhelm B; Wissinger B; Wozar F; Zrenner E; Fischer MD; Stingl K
    Br J Ophthalmol; 2022 Jun; 106(6):831-838. PubMed ID: 33472769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
    Kang C; Scott LJ
    Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Objective Outcomes to Evaluate Voretigene Neparvovec Treatment Effects in Clinical Practice.
    Melillo P; Testa F; Di Iorio V; Karali M; Citro A; Della Corte M; Rossi S; Banfi S; Simonelli F
    Ophthalmol Retina; 2024 Jul; 8(7):688-698. PubMed ID: 38295874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
    Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
    Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic
    Kiraly P; Cottriall CL; Taylor LJ; Jolly JK; Cehajic-Kapetanovic J; Yusuf IH; Martinez-Fernandez de la Camara C; Shanks M; Downes SM; MacLaren RE; Fischer MD
    Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full-field Scotopic Threshold Improvement after Voretigene Neparvovec-rzyl Treatment Correlates with Chorioretinal Atrophy.
    Stingl K; Stingl K; Schwartz H; Reid MW; Kempf M; Dimopoulos S; Kortuem F; Borchert MS; Lee TC; Nagiel A
    Ophthalmology; 2023 Jul; 130(7):764-770. PubMed ID: 36822437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation after Voretigene Neparvovec Administration in Patients with RPE65-Related Retinal Dystrophy.
    Kessel L; Christensen UC; Klemp K
    Ophthalmology; 2022 Nov; 129(11):1287-1293. PubMed ID: 35760216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The first gene therapy for
    Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
    Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.
    Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K
    Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.
    Sengillo JD; Gregori NZ; Sisk RA; Weng CY; Berrocal AM; Davis JL; Mendoza-Santiesteban CE; Zheng DD; Feuer WJ; Lam BL
    Ophthalmol Retina; 2022 Apr; 6(4):273-283. PubMed ID: 34896323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subretinal deposits in young patients treated with voretigene neparvovec-rzyl for RPE65-mediated retinal dystrophy.
    Lopez J; Borchert M; Lee TC; Nagiel A
    Br J Ophthalmol; 2023 Mar; 107(3):299-301. PubMed ID: 35835501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
    Deng C; Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera TK; Khan N; Besirli CG
    Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1543-1550. PubMed ID: 35001204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy.
    Testa F; Melillo P; Di Iorio V; Iovino C; Farinaro F; Karali M; Banfi S; Rossi S; Della Corte M; Simonelli F
    Sci Rep; 2022 Oct; 12(1):17637. PubMed ID: 36271235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing Photoreceptor Status in Retinal Dystrophies: From High-Resolution Imaging to Functional Vision.
    Sahel JA; Grieve K; Pagot C; Authié C; Mohand-Said S; Paques M; Audo I; Becker K; Chaumet-Riffaud AE; Azoulay L; Gutman E; Léveillard T; Zeitz C; Picaud S; Dalkara D; Marazova K
    Am J Ophthalmol; 2021 Oct; 230():12-47. PubMed ID: 34000280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK.
    Viriato D; Bennett N; Sidhu R; Hancock E; Lomax H; Trueman D; MacLaren RE
    Adv Ther; 2020 Mar; 37(3):1233-1247. PubMed ID: 32034665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.